Glycoprotein IIb–IIIa Inhibitors for Acute Ischemic Stroke | Zendy

Alfonso Ciccone | Zendy; Cristina Motto | Zendy; Iosief Abraha | Zendy; Francesco Cozzolino | Zendy; Ignazio Santilli | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Glycoprotein IIb–IIIa Inhibitors for Acute Ischemic Stroke

Author(s) -

Alfonso Ciccone,

Cristina Motto,

Iosief Abraha,

Francesco Cozzolino,

Ignazio Santilli

Publication year - 2014

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.114.005520

Subject(s) - medicine , stroke (engine) , regional hospital , neurology , unit (ring theory) , emergency medicine , ischemic stroke , family medicine , psychiatry , ischemia , mathematics education , mathematics , mechanical engineering , engineering

Section Editor: Graeme J. Hankey MD, FRCP Glycoprotein (GP) IIb-IIIa inhibitors block the final common pathway to platelet aggregation antagonizing with receptors that bind fibrinogen molecules forming bridges between adjacent platelets. Thus, GP IIb-IIIa inhibitors could favor endogenous thrombolysis by reducing thrombus growth and prevent thrombus reformation by competitive inhibition with fibrinogen. Currently used in clinical practice for acute coronary syndromes and percutaneous coronary interventions, they could be useful also for patients with acute ischemic stroke.To perform a systematic review of controlled clinical trials in order to assemble all the available data to evaluate the potential efficacy and safety of GP IIb-IIIa inhibitors in patients with acute ischemic stroke.We searched the Cochrane Stroke Group Trials Register (last searched May 31, 2005). In addition we …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research